Biohaven Pharmaceutical Holding Co. Ltd. has acquired the remaining 58% interest of Kleo Pharmaceuticals, Inc. and has entered an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven assumed Kleo’s laboratory facilities located in Science Park in New Haven, CT and formed Biohaven Labs to serve as the integrated chemistry and discovery research arm of Biohaven.
 

Biohaven Labs will continue several existing Kleo discovery partnerships, including with the Bill and Melinda Gates Foundation for the development of a Hyperimmune Globulin Mimic (HGM) for COVID-19 and PeptiDream for the development of immuno-oncology therapeutics.
 
Kleo is a privately held biotechnology company developing next-generation, bispecific compounds designed to emulate or enhance the activity of biologics based on the groundbreaking research of its scientific founder Dr. David Spiegel at Yale University. Its technology platforms are modular in design and enable rapid generation of novel immunotherapies that can be optimized against specified biological targets and combined with existing cell- or antibody-based therapies. These include Antibody Recruiting Molecules (ARMs) and Monoclonal Antibody Therapy Enhancers (MATEs).
 
The Kleo chemistry and discovery staff will join Biohaven’s class clinical development operations. Biohaven Labs will assume full control of the approximately 10,000 square feet of the recently established Kleo chemistry and discovery facilities at Science Park. Biohaven Labs will continue its collaboration with PeptiDream and plans on expanding its partnership.